Follow
Anna Fink
Anna Fink
Klinik I für Innere Medizin, Uniklinik Köln
Verified email at uk-koeln.de
Title
Cited by
Cited by
Year
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ...
The Lancet 376 (9747), 1164-1174, 2010
23772010
Mutations driving CLL and their evolution in progression and relapse
DA Landau, E Tausch, AN Taylor-Weiner, C Stewart, JG Reiter, J Bahlo, ...
Nature 526 (7574), 525-530, 2015
11302015
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ...
New England Journal of Medicine 380 (23), 2225-2236, 2019
8512019
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ...
Blood, The Journal of the American Society of Hematology 127 (2), 208-215, 2016
7922016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10 …
B Eichhorst, AM Fink, J Bahlo, R Busch, G Kovacs, C Maurer, E Lange, ...
The lancet oncology 17 (7), 928-942, 2016
733*2016
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ...
Blood, The Journal of the American Society of Hematology 123 (21), 3247-3254, 2014
6242014
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic …
K Fischer, P Cramer, R Busch, S Böttcher, J Bahlo, J Schubert, KH Pflüger, ...
Journal of Clinical Oncology 30 (26), 3209-3216, 2012
5632012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the …
S Böttcher, M Ritgen, K Fischer, S Stilgenbauer, RM Busch, ...
J Clin Oncol 30 (9), 980-988, 2012
5542012
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
BF Eichhorst, R Busch, S Stilgenbauer, M Stauch, MA Bergmann, ...
Blood, The Journal of the American Society of Hematology 114 (16), 3382-3391, 2009
4532009
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
N Pflug, J Bahlo, TD Shanafelt, BF Eichhorst, MA Bergmann, T Elter, ...
Blood, The Journal of the American Society of Hematology 124 (1), 49-62, 2014
3592014
Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free …
M Hallek, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, M Hensel, ...
Blood 112 (11), 325, 2008
3422008
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open …
O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, ...
The Lancet Oncology 21 (9), 1188-1200, 2020
2942020
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program
DL Pagano, C Girmenia, L Mele, P Ricci, ME Tosti, A Nosari, M Buelli, ...
haematologica 86 (8), 862-870, 2001
2112001
Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of …
G Kovacs, S Robrecht, AM Fink, J Bahlo, P Cramer, J von Tresckow, ...
Journal of Clinical Oncology 34 (31), 3758-3765, 2016
2052016
First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced …
M Hallek, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, M Hensel, ...
Blood 114 (22), 535, 2009
1402009
Venetoclax and obinutuzumab in chronic lymphocytic leukemia
K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ...
Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017
1322017
cyclophosphamide (C), and rituximab (R)(FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients …
B Eichhorst, AM Fink, R Busch, G Kovacs, C Maurer, E Lange
Blood 124 (21), 19, 2014
1232014
Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG)
K Fischer, S Stilgenbauer, CD Schweighofer, R Busch, J Renschler, ...
Blood 112 (11), 330, 2008
1162008
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
E Tausch, C Schneider, S Robrecht, C Zhang, A Dolnik, J Bloehdorn, ...
Blood, The Journal of the American Society of Hematology 135 (26), 2402-2412, 2020
1122020
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
P Cramer, J von Tresckow, J Bahlo, S Robrecht, P Langerbeins, ...
The Lancet Oncology 19 (9), 1215-1228, 2018
1122018
The system can't perform the operation now. Try again later.
Articles 1–20